A/Prof Peter Gorayski is committed to delivering evidence-based, personalised cancer care. He is passionate about ensuring patients in his care can access high quality, state-of-the-art radiation therapy treatment as close to home as possible.
A/Prof Peter Gorayski is an experienced radiation oncologist consulting at Icon Cancer Centre Windsor Gardens. He completed his medical degree (BMBS) at Flinders University in 2005. Prior to this he completed his undergraduate degree (BSc Hons) at Michigan State University in the United States. A/Prof Gorayski completed specialist training in General Practice/Family Medicine (FRACGP) in 2010 before undertaking radiation oncology training in Queensland, obtaining fellowship (FRANZCR) in 2015. Prior to relocating to South Australia, A/Prof Peter Gorayski worked as a radiation oncologist in Toowoomba, Ipswich and the Gold Coast. A/Prof Gorayski is a staff specialist at the Royal Adelaide Hospital and has a key role in their proton versus photon comparative planning service.
A/Prof Gorayski maintains a strong interest in education, research and clinical trials. He is a research supervisor for training specialists and holds academic appointments as Associate Professor at the University of South Australia and Senior Lecturer in Medicine at the University of Queensland. A/Prof Gorayski reviews scientific papers for leading national and international medical journals and is an examiner for the Royal Australian and New Zealand College of Radiologists (RANZCR).
A/Prof Gorayski specialises in the use of advanced technologies including volumetric modulated arc therapy (VMAT), intensity modulated radiation therapy (IMRT), image guided radiotherapy (IGRT) and stereotactic radiation therapy techniques. His clinical experience covers a broad range of solid tumour malignancies, with special clinical interests in brain, genitourinary, head and neck, lung, breast, gastrointestinal cancers, lymphoma, skin cancer and melanoma. He sees all patients for consideration of palliative radiation therapy for metastatic cancer to maximise quality of life.